Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020

Rhea-AI Summary

Brickell Biotech, Inc. (Nasdaq: BBI) will report its financial results for Q3 2020 on November 12, 2020, after market close. A conference call hosted by management will occur at 4:30 PM ET on the same day to discuss these results and other corporate highlights. Brickell focuses on developing innovative therapeutics for skin diseases, with a pipeline targeting conditions like hyperhidrosis. The management team has substantial experience in product development from leading pharmaceutical and biotech firms.

Positive

• Upcoming financial results report for Q3 2020 scheduled for November 12, 2020.
• Focus on innovative therapeutics for skin diseases, indicating growth potential.
• Experienced management team brings valuable expertise in product development.

Negative

• None.

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, November 12^th to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13708850. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

When will Brickell Biotech report its Q3 financial results?

Brickell Biotech will report its Q3 financial results on November 12, 2020, after market close.

What time is the Brickell Biotech conference call?

The conference call hosted by Brickell Biotech management will occur at 4:30 PM ET on November 12, 2020.

What is the primary focus of Brickell Biotech?

Brickell Biotech focuses on developing innovative and differentiated prescription therapeutics for debilitating skin diseases.

How can I access the Brickell Biotech conference call?

To access the call, dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. with conference ID 13708850.